BAY1161909 is one of two clinical candidates disclosed in a single paper from Bayer. The compounds have an interesting anti-cancer mechanism – rather than inhibiting cancer cell growth, they accelerate cancer cell cycle progression, leading to cell death due to a high degree of chromosomal misaggregation. 909 was discovered through an HTS and [...]
< 1 minute read
Sep. 17, 2021
BAY1161909: A Pro-Mitotic Selective MPS1 Kinase Inhibitor
BAY1161909
pro-mitotic selective MPS1 kinase inhibitor dev. paused for 2nd candidate (BAY1217389) from 2M cmpd biochem. HTS and SBDD J. Med. Chem., Apr. 27, 2020 Bayer AG, Berlin, DE
Loading...
